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Introduction
Viral hepatitis infection is the leading cause of cirrhosis and primary 
liver cancer in Africa [1], where HBsAg prevalence is up to 20% in 
the general population [2]. Owing to shared routes of transmission, 
hepatitis infection rates among HIV-infected patients are significantly 
higher than in the general population [3,4]. 
Since the global scale-up of HAART, numerous studies have 
shown that the efficacy of HAART in suppression of HIV in Africa is 
comparable to that obtained in resource-rich countries [5-7], though 
there are conflicting data on whether HBV co-infection affects HIV 
suppression [8-10]. In the developed world setting, liver disease has 
emerged as a leading cause of death in the era of HAART [11-13] and 
viral hepatitis co-infection plays an important role in the progression 
to cirrhosis in hepatitis B and hepatitis C patients, who are co-infected 
with HIV [14]. This pattern has continued despite increasing availability 
and administration of HBV-active HAART.
The role of viral hepatitis and consequent chronic liver disease 
on mortality has not been widely studied in HIV-infected African 
populations [15,16], but some studies have noted high death rates 
during the initial period of ART [17,18]. However, most of the 
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published studies have been small [5-7]. We have recently published 
a high prevalence (18%) of HBsAg in 19,408 HIV-infected patients 
from an African population [19]. In the current report, we present 
the largest study to date that explores the role of HBV and HIV co-
infection on survival of HIV patients in an African setting. Knowledge 
of the prognostic effect of liver-related conditions, such as hepatitis B, 
which is highly endemic in the West African region, would help inform 
guidelines on screening and treatment with a potential to reduce excess 
mortality in HIV-infected patients. 
Nigeria is categorised as a low income country, with a population 
of over 150 million and an estimated HIV prevalence of 4.4% [20] and 
HBsAg prevalence rates of up to 20% [21]. The aims of the present 
study were to assess the impact of hepatitis B infection, determined 
by HBsAg seropositivity, on the survival of HIV-infected individuals 
and to identify predictors of mortality during the HAART era in a large 
cohort of Nigerian patients.
Methods
Study setting and patients
The study was conducted as part of the “AIDS Prevention Initiative 
in Nigeria” (APIN) programme, affiliated to the Jos University Teaching 
Hospital (JUTH), Jos, Plateau State in the north-central region of 
Nigeria. Most patients enrolled into the JUTH/APIN programme were 
detected through Voluntary Counselling and Testing (VCT) services 
in adjacent communities. Hospitalised patients were investigated on 
clinical suspicion or referred from nearby health centres. Subjects 
found to be reactive to HIV by ELISA were confirmed by Western 
blot assay prior to enrolment. Liver function tests (LFTs), full blood 
count, HIV RNA and CD4 cell counts were measured in all recruited 
patients at baseline who were also screened for tuberculosis (TB), prior 
to commencement of HAART, following the Nigeria national HIV 
treatment guidelines (www.naca.gov.ng). From June 2004 to December 
2010, 19,408 HIV-infected individuals had been recruited in the 
JUTH/APIN programme and were being monitored, on HAART and/
or on anti-tuberculosis drugs. This number was estimated at 13% of 
all HIV-infected patients within the catchment area [20]. Onsite and 
offsite training was provided to personnel working at JUTH/APIN by 
HIV specialists from the Harvard School of Public Health (Boston, 
Massachusetts), Northwestern University (Chicago, Illinois) and Johns 
Hopkins University (Baltimore, Maryland), USA. 
All patients were subjected to pre-treatment counselling. A patient 
tracking team, responsible for providing support to all enrolled patients 
(in terms of adherence fostering and to trace missing patients) was put 
in place in 2006. Treatment support groups (Hope Support), comprising 
mostly of HIV-infected patients, were set up within the clinic and 
surrounding communities. 
PK, the guarantor of the study) obtained ethical approval for the 
present study from the Ethics Committee of JUTH and an additional 
Institutional Review Board (IRB) of Harvard School of Public Health, 
USA.
Laboratory testing
Before recruitment into the APIN programme, subjects were 
screened for HIV using Rapid HIV test kits and subsequently 
confirmed by Western Blot assay. HBsAg was determined using Enzyme 
immunoassay (EIA) (Monolisa HBsAg Ultra3; BioRad, Hercules, 
CA, USA). HCV antibody was tested using third generation enzyme 
immunoassay (DIA.PRO Diagnostic, Bioprobessrl, Milan, Italy). HIV 
RNA levels were measured using Roche COBAS Amplicor HIV-1 
monitor test version 1.5 (Roche Diagnostics, GmbH, Mannheim, 
Germany) with a detection limit of 400 copies/mL (Figure 1). Flow 
cytometry was used to determine CD4+ T-cell count (Partec, GmbH, 
Munster, Germany).
Recruitment, treatment, monitoring and endpoints
Initial first-line antiretroviral (ARV) in 2004 included Stavudine/
Zidovudine, Lamivudine and Efavirenz/Nevirapine. Abacavir and 
Truvada® (Tenofovir plus Emtricitabine) have been administered 
since 2007 at APIN. Additionally, second-line treatment with protease 
inhibitors, in cases of treatment failure also became available since early 
2007. However, during 2004 to 2006, Tenofovir and second-line agents 
were not available and HAART was not individualised. During 2007-
2010, those patients commencing HAART that were co-infected with 
HBV, as well as those requiring second line agents, for virological failure 
were given ARVs containing Tenofovir. 
Patients with CD4 cell counts below 200 cells/mm3were 
prescribed co-trimoxazole 960mg once a day, as prophylaxis for 
P.neumocystisjiroveci pneumonia (PCP). After an initial 4 weeks of 
fortnightly dispensing, HAART drugs were provided on a monthly 
basis to those patients on ART. Paper-based format of data entry was 
ensured by nurses, physicians and trained clinical officers and same 
day computerised data entry was carried out by Data Officers and 
supervised by a Data Manager. Personal information, medical history, 
physical examination, laboratory investigation and chest X ray reports 
comprised the initial records. Follow-up blood tests performed every 
3 months, including LFTs, FBC, HIVRNA and CD4 cell count. Drug-
related hepatotoxicity was defined as alanine aminotransferase (ALT) 
Subjects enrolled at APIN from June
2004 to March  2012
Assessed for eligibility
 Excluded (total=7,480)
Further exclusions
Yet to commence
HAART, n=639
Triple infection
n=266
HCV infection,
n=1,287
Analysed 
Total started on HAART, n=9,758
On HAART during initial 12 months,
n=1,419
Absent info on gender,
n=6
Absent info on age, n=5
Age below 15, n=13
Hepatitis screening
result absent for HBV,
and/or HCV, n=7,456
Not assessed for eligibility
Recruited after Dec 2010
n=203
n=19,430
n=19,633
(HBV/HCV/HIV),
Total assessed with baseline parameters
n=11,950
Figure 1: Profile of study cohort, AIDS Prevention Initiative in Nigeria, Jos 
University Teaching Hospital, Nigeria, 2004-2010.
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values ≥ 5 fold over the upper limit of the normal range (ULN) (41 iu/
mL for JUTH), or if ≥ 3.5 fold over ULN if baseline ALT was above 
ULN.
As HBV DNA and HCV RNA assays were not available routinely 
for this cohort, subjects were defined as having HBV and HCV 
infection if they tested positive for hepatitis B surface antigen (HBsAg) 
and hepatitis C antibody (HCV antibody), respectively on baseline 
blood samples.
The main end-point of our study was all-cause mortality. Most 
deaths were reported through the activities of the Tracking team and 
Hope Support groups. Other outcomes that were censored included 
those that stopped treatment (detected by pharmacy records), transfer 
to another health centre or lost to follow-up.
Statistical analyses
The profile of how the patients were selected for analyses is 
presented in figure 1. Patients were included only if they had hepatitis 
B and hepatitis C screening performed on their sera at baseline. Apart 
from over 7000 patients who did not have one or both HBV and HCV 
screening, we additionally excluded those that were recruited after 
December 2010, and those with incomplete information (gender, age 
or under 15 yrs).
Kaplan-Meier models were used to estimate survival of the patient 
groups, while a Cox proportional hazard modelling was applied to 
identify independent predictors of mortality. Univariate analysis was 
embarked upon initially; and when a statistically significant association 
was detected, the variable was fitted into the multivariate model and 
hazard ratios calculated. Subsequently, we analysed the hazards of 
death for those patients on TDF-containing HAART, as well as for those 
not on TDF-containing HAART. Analyses were accomplished using 
MedCalc for Windows, version 9.5.0.0 (MedCalc Software, Mariakerke, 
Belgium). P values less than 0.05 were considered statistically significant. 
Results
Baseline characteristics
Of the 9,748 adults that were commenced on HAART, 6,523 (66.9%) 
were women. The median age of the study population was 33 years 
(range 15-80 yrs.) and 5,915 (60.7%) of the patients had commenced 
HAART during the initial period, 2004-2006. The period of the study 
was defined based on availability of Tenofovir (HBV potent ARV) in 
the regimen for the patients commencing HAART. On this basis, initial 
period was 2004-2006 and later period was 2007-2010. 
Summary of the baseline characteristics of patients recruited in 
the study is presented in Table 1. TB treatment was administered to 
Characteristic Total n=9,758 Deaths n (%) p value Male n=3,229 Deaths n (%) Female n=6,530 Deaths n %)
Age-group (years) 0.008*
15-29 3,147 45(1.4) 393 4(4.0) 2,754 41(1.5)
30-39 3,967 73(1.8) 1,378 31(2.2) 2,589 42(1.6)
40-49 2,001 47(2.3) 1,069 35(3.3) 932 12(1.3)
50+ 644 16(2.5) 389 9(2.3) 255 7(2.7)
HBsAg status 0.034
HBsAg +ve 1,950 48(2.5) 721 25(3.5) 1,230 23(1.9)
HBsAg –ve 7,808 133(1.7) 2,508 54(2.2) 5,300 79(1.5)
Liver disease 0.9
Present 23 0(0.0) 5 0(0.0) 18 0(0.0)
Absent 9,728 181(1.9) 3,220 79(2.5) 6,508 102(1.9)
TB diagnosis <0.0001
Present 1,640 55(3.4) 743 30(4.0) 898 25(2.8)
Absent 8,118 126(1.6) 2,486 49(2.0) 5,632 77(1.4)
HIV RNA at baseline (viral copies/mL) 0.06*
<400 1,267 25(2.0) 408 11(2.7) 859 14(1.6)
400-9,999 1,950 23(1.2) 565 9(1.6) 1,385 14(1.0)
10,000-29,999 1,523 22(1.4) 427 10(2.3) 1,096 12(1.1)
≥30,000 5,019 111(2.2) 1,829 49(2.7) 3,190 62(1.9)
CD4 cell count at baseline (cells/mL) 0.003*
<200 1,599 24(1.5) 605 7(1.2) 994 17(1.7)
200-499 1,050 4(0.4) 295 1(0.3) 755 3(0.4)
≥500 136 0(0.0) 24 0(0.0) 112 0(0.0)
Period of enrolment <0.0001
2004-2006 5,920 143(2.4) 1,963 67(3.4) 3,958 76(1.9)
2007-2010 3,838 38(1.0) 1,266 12(0.9) 2,572 26(1.0)
*p values indicate comparison for trend
Table 1: Baseline characteristics and associated deaths among HIV-infected patients in Nigeria, 2004-2010.
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1,641 (16.8%) patients. For those that had CD4 results at baseline, 
there was a significantly higher median CD4 cell count in women than 
in men (M: 146 (95% CI=136-156) cells/mm3; F: 188 (95%CI=179-
195) cells/mm3; p<0.0001). The median baseline HIV RNA load was 
log104.52 (95% CI=4.50-4.55)(M:4.6(95%CI=4.6-4.7) copies/mL; 
F:4.5(95%CI=4.4-4.5) copies/mL; p<0.0001). HBsAg-positive rate 
was common in this study cohort; 1951 (20.0%). Liver disease was 
documented in only 23 (0.2%) of the patients.
Survival analyses
Of those patients that were on HAART, 181 patients (1.9%) died 
during the follow-up period. One hundred and forty-three (79.0%) of 
those that died started ART during the initial period (2004-2006). Male 
gender, age ≥40 years at recruitment, co-morbid tuberculosis, HBsAg 
positivity, and recruitment during the initial phase of the study were 
all significantly associated with death (Table 2). Patients that were co-
infected with HBV suffered a lower survival rate, compared to patient’s 
negative for HBsAg (Figure 2). The survival probability of HBsAg-
positive versus HBsAg-negative patients at 78 months of follow-up 
was 94% and 97%, respectively (p=0.01). This was the case particularly 
for men; as HBV co-infection did not result in survival differences in 
women. HBsAg-positive men had lower survival, compared to HIV 
mono-infected men (HIV-positive/HBsAg-positive: 88.5%; HIV-
positive/HBsAg-negative: 96.5%; p=0.04). 
Fitting the non AIDS-related factors (ie excluding HIV viral load 
and CD4 cell count) into the Cox regression multivariate model, 
independent predictors of death were found to be male sex, co-
morbid tuberculosis and HBV infection. The hazard of mortality was 
significantly reduced in patients who started HAART during 2007-2010 
(HR: 0.64 [95% CI: 0.42-0.88]), compared to those enrolled during 
the earlier phase of the programme (p=0.0081). Intriguingly, HBsAg-
positivity, male gender and enrolment that is more recent ceased to be 
significant in those that were on TDF-containing HAART.
As the majority of the deaths occurred during the initial follow-up 
period, we performed an additional Cox proportional hazard analysis 
of death during 12 months from recruitment into the study. Age ≥ 40 
yrs at recruitment, HBV infection (HBsAg-positive) and enrolment 
 HAART Covariate HR (95% CI) SE Coefficient p value
All time Male 1.5(1.08-2.00) 0.15 0.4 0.0134
HBsAg +ve 1.5(1.09-2.11) 0.17 0.4 0.0129
Later recruitment (2007-2010) 0.6(0.42-0.88) 0.19 -0.5 0.0081
TB diagnosis 2.2(1.57-2.96) 0.16 0.8 <0.0001
Initial 12 months
HBsAg +ve 2.1(1.32-3.21) 0.23 0.7 0.0015
40-49 years 1.9(1.16-3.07) 0.25 0.6 0.011
≥50 years 2.5(1.31-4.80) 0.33 0.9 0.0057
Earlier recruitment (2004-2006) 6.3(3.86-10.31) 0.25 1.8 <0.0001
None-TDF-based HAART Male 1.8(1.16-2.68) 0.21 0.6 0.0084
HBsAg +ve 4.3(2.60-6.95) 0.25 1.4 <0.0001
Latter recruitment (2007-2010) 0.3(0.14-0.57) 0.36 -1.2 0.0004
TDF-based HAART TB  diagnosis 2.9(1.94-4.39) 0.21 1.1 <0.0001
TDF = Tenofovir
Table 2: Multivariate analyses of predictors of mortality in HIV-infected individuals, AIDS Prevention Initiative in Nigeria JUTH, 2004-2010.
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Figure 2: Kaplan-Meier survival curves according to hepatitis co-infection 
status for: both sexes; and men; APIN 2004-2010; HBV: Hepatitis B virus; 
HCV: hepatitis C virus.
Citation: Ladep NG, Agbaji OO, Agaba PA, Muazu A, Ugoagwu P, et al (2013) Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected 
Patients on Highly Active Antiretroviral Therapy in West Africa. J AIDS Clinic Res S3: 006. doi:10.4172/2155-6113.S3-006
Page 5 of 6
J AIDS Clinic Res Co-infections: HIV ISSN:2155-6113 JAR, an open access journal 
during 2004-2006 were significant predictors of mortality during the 
early follow-up period.
Discussion
In this African HIV-infected cohort of 9,758 patients on HAART, 
followed up for a median period of 41 months, we determined the impact 
of HBV infection on survival and studied independent predictors of 
mortality of HIV-infected patients undergoing antiretroviral therapy. 
HIV/HBV co-infection was found to be significantly associated with 
a lower probability of survival, compared to HIV mono-infection. On 
the other hand, recent recruitment into the APIN programme was 
significantly associated with reduced rate of death in both groups. 
Apart from HBV co-infection, tuberculosis and male sex were also 
significantly associated with mortality. 
Two studies from South Africa found conflicting outcomes 
regarding the impact of HBV co-infection on HIV mortality [8,10]. 
Hoffman and colleagues in 2008 reported similar probability of deaths 
in HBV/HIV and HIV mono-infected patients over a 72-week period 
[10]. In contrast, Matthews and colleagues observed a significantly 
higher mortality in HBV co-infected patients, compared to HIV mono-
infected 1,771 patients in South Africa over 48 weeks follow-up duration 
[8]. Our findings corroborated those of a large study of HIV-infected 
men in the US in which non AIDS-related mortality was highest among 
HIV/HBV-infected patients, despite being on HBV-active HAART [9] 
and in which no association between HBV infection and higher rates 
of HIV virologic failure was found. In contrast to the study in the US 
however, we found that HBV was not a predictor of mortality when 
these African HIV patients were on Tenofovir-containing HAART.
The reasons for the negative impact of HBsAg status on mortality 
are not fully understood, but it is unlikely to be related to accentuation 
of HIV replication, as we found similar levels of virologic suppression 
in co-infected versus HIV mono-infected patients in an earlier study 
of this cohort [19]. HBV infection in this population frequently occurs 
early in life and is postulated to precede HIV infection [22] by which 
time liver damage may be irreversible, annulling the anticipated 
response from HAART. Inflammatory response commonly occurs 
during the early phase of HAART [23] and could have contributed to 
the flaring of HBV infection [24].
We noted a higher mortality during the early phase of HAART 
in this study population. It is possible that this effect is due to late 
presentation of patients with more advanced disease. However, analysis 
restricted to only those who are taking Tenofovir suggests a beneficial 
impact in those with HBV. 
Tuberculosis is a common co-morbidity of HIV-infected patients 
and was an independent predictor of mortality in the present study, 
in agreement with the results of other studies across Africa [25-27]. 
It is known that the relative risk of anti-tuberculous therapy-induced 
hepatotoxicity is higher in HBV/HIV co-infected patients than in HIV 
mono-infected individuals [28]. Symptomatic liver disease (particularly, 
jaundice) frequently prompts patients to seek alternative drugs, a 
common feature in African HIV populations [29,30], and/or which 
lead to treatment interruption and change to less potent regimens. If 
this had contributed in deaths in the present study cohort, such patients 
might have died at home, or away from the hospital affiliated to APIN 
and therefore may have be under represented in our data set.
Male gender was a significant predictor of mortality in the study 
cohort. Men had lower CD4 cell count at HAART commencement than 
women. Indeed, the CD4 cell count at commencement of HAART has 
been found to correlate with response and ultimately, survival [31]. Our 
data confirm this, as a significant trend of decreased death rate with 
increasing CD4 cell count prior to commencing HAART was found. 
Additionally, studies have reported that women generally do better 
than men to HIV treatment [32]. The prevention of mother to child 
transmission of HIV (PMTCT) services, which predated the onset of 
APIN, might have enabled more women to be used to HIV care and 
tolerating the side effects of ARVs than men. 
Limitations encountered in our study include the following: First, 
the causes of death were not well ascertained asa result of suboptimal 
documentation. Precise dates of death of several patients were not 
recorded and we depended on information from carers, Hope Support 
and Tracking teams. We were thus limited in describing disease-specific 
deaths. Whenever any of the patients had any serious illness, such as 
liver disease, they were referred to specialist consultation in the affiliated 
hospital (JUTH). As no linkage of records exists currently between 
JUTH and APIN, considerable amounts of information that would 
have been relevant to our analyses may have been missed. Additionally, 
censoring subjects who discontinued treatment, transferred to other 
centres of care and or lost to follow up may have introduced bias to the 
obtained results.
Second, confirmation of HBV viraemic status by molecular 
methods was not carried out in this population as this current study 
was designed to utilise already obtained data and molecular diagnosis 
of hepatitis is not routine in the study population (we had shown, in 
an unpublished data that HBV viraemia was positive in about 98% of 
HBsAg-positive subpopulation of this study cohort). It would be of 
interest to appropriately categorise the patients by their viraemic status, 
which would indeed enhance the power of this study. 
In conclusion, HBV infection, tuberculosis and male gender were 
significantly associated with mortality, following commencement of 
HAART therapy. Patients recruited during the period, coinciding 
with increased access to Tenofovir-based treatment experienced less 
deaths. Indeed, HBV was not a significant predictor of mortality in 
those patients that were being administered Tenofovir-containing 
HAART. Long-term follow-up and enhanced monitoring are needed 
to assess incidence of end-stage liver disease, hepatocellular carcinoma 
and disease-specific deaths in this cohort. These data support an 
active approach to identifying all HIV/HBV co-infected individuals in 
resource poor settings, if Tenofovir is not routinely offered as first line 
treatment [33].
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